- EA
- East Asia
East Africa
Emergency Appeal
Expanded Access
Note: multiple definitions exist for this acronym[4], so don't abbreviate unless the precise meaning is clear from the context.
East Asia and East Africa (EA): See also WHO regions and IFRC regions
Emergency Appleal (EA): An appeal, in this sense, is a call on (someone) for aid. The WHO has an important role, especially when it issues a public health emergency of international concern (PHEIC), see for example COVID-19.[1]
WHO[2] and IFRC[3] both play important roles in EAs.
Expanded Access (EA), or compassionate use, is the enabling of patients with serious diseases to access new drugs or therapies normally only available as part of clinical trials. See more details below.[5]
FDA - Expanded Access
Sometimes called “compassionate use”, expanded access is a potential pathway for a patient with an immediately life-threatening condition or serious disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.
Expanded access may, according to the FDA, be appropriate when all the following apply:
- Patient has a serious or immediately life-threatening disease or condition
- There is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition
- Patient enrollment in a clinical trial is not possible
- Potential patient benefit justifies the potential risks of treatment
- The investigational medical product will not interfere with investigational trials that could support a medical product’s development or marketing approval for the treatment indication